Evaluation of Histamine H3 Receptor Radioligand [11C]AZ12807110 and Histamine H3 Receptor Occupancy of AZD5213 After Oral Administration

• Status: Completed
• Trial end date: 2011-06-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to investigate features of radioligand [11C]AZ12807110 and how much AZD5213 displaces radioligand from histamine receptors when given together.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: AstraZeneca
• Treatments: Histamine; Histamine phosphate

Criteria

Inclusion Criteria:

• Healthy male and/or female volunteers between 20 to 45 years with suitable veins for cannulation or repeated venipuncture (pilot panel)

• Female must be of non-child bearing potential (pilot panel)

• BMI between 18 to 30 30 kg/m2

• Normal MRI scan

• Provision of signed, written and dated informed consent

Exclusion Criteria:

• History of any clinically significant disease or disorder

• History or presence of gastrointestinal, hepatic or renal disease

• Prolonged QTcF >450 ms or shortened QTcF <340 ms or family history of long QT syndrome

• History of severe allergy or hypersensitivity or ongoing allergy or hypersensitivity

• Healthy volunteer suffers from claustrophobia